All In Biotech

Drug Trial Radar · NCT03394365

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

115

Planned (sponsor's estimate)

Start

Dec 29, 2017

Primary completion

May 31, 2030

Study completion Aug 2030

Sponsor

Lead sponsor
Pierre Fabre MedicamentIndustry
Sponsor type
Industry
First posted
Jan 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.

Conditions

  • Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
  • Solid Organ Transplant Complications
  • Lymphoproliferative Disorders
  • Allogeneic Hematopoietic Cell Transplant
  • Stem Cell Transplant Complications

Interventions

  • tabelecleucelBiological

    Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) in the Analysis Cohorts C-SOT, C-HCT, and Combined Population (C-SOT-R+C, C-SOT-R-Ci, and C-HCT) Who Received Commercial Product, or a Product Manufactured Using a Comparable PVTime frame: 2 years

Locations

71 sites in 9 countries. Site status is shown where the registry gives one.

  • City of Hope (Adults and Pediatrics)

    Duarte, California · Completed

  • University of California San Diego Moores Cancer Center (Adults only)

    La Jolla, California · Completed

  • Loma Linda University Medical Center (Adults only)

    Loma Linda, California · Recruiting

  • Children's Hospital Los Angeles, Div. of Research Immunology/BMT (Adults and Pediatrics)

    Los Angeles, California · Recruiting

  • UCLA Medical Center (Adults and Pediatrics)

    Los Angeles, California · Completed

  • University of California Davis Comprehensive Cancer Center (Adults only)

    Sacramento, California · Completed

  • Yale University (Adults and Pediatrics)

    New Haven, Connecticut · Completed

  • MedStar Georgetown University Hospital (Adults and Pediatrics)

    Washington D.C., District of Columbia · Recruiting

  • University of Florida (Adults and Pediatrics)

    Gainesville, Florida · Completed

  • University of Miami/Jackson Memorial Hospital (Adults only)

    Miami, Florida · Recruiting

  • Winship Cancer Institute (Adults only)

    Atlanta, Georgia · Completed

  • Arthur M Blank Hospital - Children's Healthcare of Atlanta

    Atlanta, Georgia · Recruiting

  • Ann & Robert H. Lurie Children's Hospital of Chicago (Adults and Pediatrics)

    Chicago, Illinois · Recruiting

  • University of Chicago Medical Center - Duchossois Center for Advanced Medicine (Adults only)

    Chicago, Illinois · Completed

  • Loyola University Medical Center (Adults and Pediatrics)

    Maywood, Illinois · Recruiting

  • University of Maryland School of Medicine (Adults only)

    Baltimore, Maryland · Completed

  • Dana Farber Cancer Institute, Brigham and Women's Hospital (Adults and Pediatrics)

    Boston, Massachusetts · Recruiting

  • Washington University School of Medicine (Adults only)

    St Louis, Missouri · Recruiting

  • Weill Cornell Medicine (Adults only)

    New York, New York · Completed

  • Columbia University Medical Center (Adults and Pediatrics)

    New York, New York · Completed

  • Memorial Sloan Kettering Cancer Center (Adults and Pediatrics)

    New York, New York · Completed

  • Montefiore Medical Center (Adults only)

    The Bronx, New York · Completed

  • Montefiore Medical Center (Pediatrics only)

    The Bronx, New York · Completed

  • University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center (Adults and Pediatrics)

    Chapel Hill, North Carolina · Completed

  • Carolinas Medical Center/Levine Children's Hospital (Adults and Pediatrics)

    Charlotte, North Carolina · Recruiting

  • Duke Cancer Institute (Adults and Pediatrics)

    Durham, North Carolina · Recruiting

  • Cleveland Clinic Foundation (Adults and Pediatrics)

    Cleveland, Ohio · Recruiting

  • Nationwide Children's Hospital (Pediatrics only)

    Columbus, Ohio · Completed

  • Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (Adults and Pediatrics)

    Columbus, Ohio · Recruiting

  • Oregon Health and Science University Physicians Pavilion (Adults and Pediatrics)

    Portland, Oregon · Recruiting

  • Hospital of the University of Pennsylvania (Adults only)

    Philadelphia, Pennsylvania · Recruiting

  • The Children's Hospital of Philadelphia Oncology Division, Blood & Marrow Transplant Section (Pediatrics)

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center (Adults only)

    Pittsburgh, Pennsylvania · Completed

  • Medical University of South Carolina (Adults and Pediatrics)

    Charleston, South Carolina · Completed

  • Saint Jude Children's Research Hospital (Pediatrics only)

    Memphis, Tennessee · Completed

  • Vanderbilt University Medical Center Henry-Joyce Cancer Clinic (Adults and Pediatrics)

    Nashville, Tennessee · Recruiting

  • Baylor Scott and White Research Institute (Adults only)

    Dallas, Texas · Recruiting

  • University of Texas Southwestern Medical Center - Children's Medical Center (Pediatrics only)

    Dallas, Texas · Recruiting

  • MD Anderson Cancer Center (Pediatrics and Adult)

    Houston, Texas · Recruiting

  • Froedtert and Medical College of Wisconsin - Clinical Cancer Center (Adults only)

    Milwaukee, Wisconsin · Completed

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.